In a trial which enrolled 2,129 Alzheimer’s patients with mild dementia, Eli Lilly’s monoclonal antibody, solanezumab, failed to slow cognitive decline. It targets soluble amyloid, which is thought to eventually aggregate into damaging plaques seen in the brain. The study’s directors, commenting on the failure, say perhaps the dose needs to be higher, or the drug needs to be administered earlier in the onset of dementia.
Our comment: A long, costly trial involving much effort. Still focusing on amyloid. But if the root cause of Alzheimer’s is something else, like an infection, anti-amyloid drugs may not make much difference.
Source: Lawrence S. Honig et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. New England Journal of Medicine, 2018; DOI: 10.1056/NEJMoa1705971, and Science Daily.